<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371615</url>
  </required_header>
  <id_info>
    <org_study_id>EBB16GL10424</org_study_id>
    <nct_id>NCT03371615</nct_id>
  </id_info>
  <brief_title>Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula</brief_title>
  <acronym>Leopard</acronym>
  <official_title>A Randomised, Controlled, Double Blind Trial to Evaluate the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula Containing Prebiotics and Locust Bean Gum in Infants With Regurgitation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricia Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricia Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new
      partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum
      in infants with regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI tolerance</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess the gastrointestinal (GI) tolerance of the investigational product compared to the control product based on Infant Gastrointestinal Symptom Questionnaire(IGSQ) symptoms score containg 13 questions on a 7 point scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Regurgitation, Gastric</condition>
  <arm_group>
    <arm_group_label>Fermented IF + LBG + Gos Fos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fermented infant formula with Locust bean gum and Gos Fos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fermented IF +LBG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fermented infant formula with Locust bean gum</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti-regurgitation infant formula</intervention_name>
    <description>Anti regurgitation infant formula</description>
    <arm_group_label>Fermented IF + LBG + Gos Fos</arm_group_label>
    <arm_group_label>Fermented IF +LBG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Singleton healthy term infant aged 3 - 13 weeks;

          2. Gestational age at birth 37- 42 weeks;

          3. Normal birth weight for gestational age and gender i.e. 10th to 90th percentile
             compared to the WHO or local growth charts;

          4. Infants with regurgitation that are otherwise healthy, based upon the following
             criteria: 1) Regurgitation of 2 or more times per day for 1 or more weeks according to
             reported history, 2) an indication for the use of AR formula according to the
             investigator at screening/randomisation.

          5. Fully formula fed for at least 7 days before screening/randomisation;

          6. Written informed consent from the parent(s) and/or legally acceptable
             representative(s), aged ≥ 18 years.

        Exclusion Criteria:

          -  1. History of retching, hematemesis, aspiration, apnoea, failure to thrive, feeding or
             swallowing difficulties or abnormal posturing; 2. Gastrointestinal infection within 4
             weeks prior to randomisation; 3. Congenital condition and/or previous or current
             illness and (or) medication use that could interfere with the main study outcomes
             according to the investigator; 4. Known cow's milk protein allergy, lactose
             intolerance, or galactosaemia including history of any other allergic manifestations
             or known allergy to any of the study product ingredients (especially scGOS); 5.
             Presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional
             in nature, as assessed by the investigator's clinical judgement; 6. Received any of
             the following products/medication prior to randomisation: systemic antibiotics,
             prokinetics, proton pump inhibitors, complementary feeding/weaning within 4 weeks
             prior to randomisation; 7. Incapability of the parent(s) to comply with the study
             protocol or investigator's uncertainty about the willingness or ability of the
             parent(s) to comply with the protocol requirements; 8. Current participation in
             another clinical intervention study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>13 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan van der Mooren, MD, phD</last_name>
    <phone>+31 30 2095573</phone>
    <email>jan.vandermooren@danone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Poliklinika Ginekologiczno-Poloznicza Sp. Z.O.O Sp.K</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Arciszewska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Promed</name>
      <address>
        <city>Kraków</city>
        <zip>31411</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieska Swiat, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Locust bean gum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

